

**STATEMENT OF INVESTMENTS**  
**Dreyfus Premier Health Care Fund**  
**January 31, 2008 (Unaudited)**

<b>Common Stocks--93.5%</b>	<b>Shares</b>	<b>Value (\$)</b>
<b>Biotechnology--27.1%</b>		
Abraxis Bioscience	572 a	34,177
Acorda Therapeutics	6,200 a	157,232
Alexion Pharmaceuticals	920 a	60,094
Amgen	2,460 a	114,611
Amylin Pharmaceuticals	4,320 a	128,088
APP Pharmaceuticals	2,280 a,b	23,963
BioMarin Pharmaceutical	6,840 a	253,490
Celgene	7,690 a	431,486
Cephalon	3,440 a	225,767
Genentech	3,915 a	274,794
Genzyme	3,160 a	246,891
Gilead Sciences	9,270 a	423,546
Illumina	2,000 a	127,400
InterMune	2,820 a	47,291
Invitrogen	1,280 a	109,658
Millennium Pharmaceuticals	13,570 a	205,857
Millipore	2,190 a	153,629
Onyx Pharmaceuticals	1,840 a	87,455
Regeneron Pharmaceuticals	5,240 a	106,267
United Therapeutics	1,470 a	123,451
Vanda Pharmaceuticals	2,540 a	10,846
Vertex Pharmaceuticals	6,400 a	130,304
ZymoGenetics	2,540 a	25,629
		<b>3,501,926</b>
<b>Distributors--2.9%</b>		
AmerisourceBergen	1,050	48,982
Henry Schein	1,370 a	79,638
McKesson	2,280	143,161
Walgreen	3,050	107,086
		<b>378,867</b>
<b>Healthcare It--2.5%</b>		
Cerner	1,540 a	80,696
Covidien	5,500	245,465
		<b>326,161</b>
<b>Managed Health Care--1.4%</b>		
Aetna	2,310	123,030
Health Net	1,150 a	53,464
		<b>176,494</b>
<b>Medical Technology--21.3%</b>		
Abiomed	2,500 a	37,750
AMAG Pharmaceuticals	1,000 a	51,560
ArthroCare	440 a,b	17,613
Baxter International	5,620	341,359
Becton, Dickinson & Co.	2,890	250,072
Gen-Probe	2,400 a	137,160

Hologic	3,690 a	237,488
Hospira	3,290 a	135,252
Medtronic	3,370	156,941
Mettler-Toledo International	1,660 a	164,838
NuVasive	4,260 a	167,887
PerkinElmer	2,900	72,181
Smith & Nephew, ADR	1,580 b	106,413
St. Jude Medical	6,600 a	267,366
Thermo Fisher Scientific	7,170 a	369,183
Varian Medical Systems	1,400 a	72,786
Zimmer Holdings	2,136 a	167,185
		<b>2,753,034</b>
<b>Pharmaceutical--18.6%</b>		
Abbott Laboratories	6,330	356,379
Allergan	3,720	249,947
Bayer, ADR	2,490	203,881
Forest Laboratories	2,090 a	83,119
Johnson & Johnson	4,570	289,098
Merck & Co.	6,250	289,250
Novartis, ADR	4,415	223,443
Roche Holding, ADR	1,435	129,896
Schering-Plough	8,160	159,691
Wyeth	6,310	251,138
XenoPort	2,760 a	169,354
		<b>2,405,196</b>
<b>Services--12.1%</b>		
Allscripts Healthcare Solutions	3,080 a	45,676
Charles River Laboratories International	3,510 a	217,971
Covance	2,795 a	232,432
CVS Caremark	9,259	361,749
Express Scripts	2,460 a	166,025
Medco Health Solutions	2,360 a	118,189
Medicines	2,950 a	50,504
Pediatrix Medical Group	1,550 a	105,540
Psychiatric Solutions	4,650 a	140,291
VCA Antech	3,290 a	127,191
		<b>1,565,568</b>
<b>Specialty Pharmaceuticals--7.6%</b>		
Alcon	1,130	160,460
Elan, ADR	9,830 a	249,780
Endo Pharmaceuticals Holdings	2,540 a	66,396
Pharmion	1,880 a	129,626
Shire, ADR	2,190	117,932
Teva Pharmaceutical Industries, ADR	5,590	257,364
		<b>981,558</b>
<b>Total Common Stocks</b>		
(cost \$11,028,011)		<b>12,088,804</b>

**Other Investment--7.2%**

---

Registered Investment Company;

Dreyfus Institutional Preferred Plus Money Market Fund (cost \$925,000)	925,000 <sup>c</sup>	<b>925,000</b>
---	----------------------	----------------

**Investment of Cash Collateral for  
Securities Loaned--1.0%**

---

**Registered Investment Company;**

Dreyfus Institutional Cash Advantage Plus Fund (cost \$134,415)	134,415 <sup>c</sup>	<b>134,415</b>
<b>Total Investments</b> (cost \$12,087,426)	<b>101.7%</b>	<b>13,148,219</b>
<b>Liabilities, Less Cash and Receivables</b>	<b>(1.7%)</b>	<b>(222,734)</b>
<b>Net Assets</b>	<b>100.0%</b>	<b>12,925,485</b>

ADR - American Depository Receipts

- a Non-income producing security.
- b All or a portion of these securities are on loan. At January 31, 2008, the total market value of the fund's securities on loan is \$132,150 and the total market value of the collateral held by the fund is \$134,415.
- c Investment in affiliated money market mutual fund.

Securities valuation policies and other investment related disclosures are hereby incorporated by reference to the annual and semi-annual reports previously filed with the Securities and Exchange Commission on Form N-CSR.